Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD   US0042251084

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

ACADIA Pharmaceuticals Inc. : & SUPERVALU Inc. Announcements: (NASDAQ: ACAD), (NYSE: SVU)

03/22/2013 | 02:25am US/Eastern
Recommend:
0

New York (March 22nd, 2013) - ACADIA Pharmaceuticals Inc.(NASDAQ: ACAD) announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting.

The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported.

“The significant and consistent results observed across measures in the Phase III -020 Study are impressive and potentially very encouraging for Parkinson’s patients who suffer from the psychosis frequently associated with this disease,” said Dr. Jeffrey Cummings.

Find out if this announcement could benefit ACAD in the very short term here:

http://www.wallstreetscoop.net/market-scan/?symbol=ACAD


SUPERVALU Inc. (NYSE: SVU) announced it completed the sale of its Albertsons, Acme, Jewel-Osco, Shaw’s and Star Market stores and related Osco and Sav-on in-store pharmacies to AB Acquisition LLC, an affiliate of a Cerberus Capital Management L.P.-led investor consortium, in a stock deal valued at $3.3 billion, including $100 million in cash and $3.2 billion in debt assumption.

Operations for these banners will transfer overnight, and the new SUPERVALU will open for business on Friday as a more efficient wholesale and retail company with annual sales of approximately $17 billion.

As part of the transaction, SUPERVALU also announced that Symphony Investors, a Cerberus-led investor consortium, completed its tender offer resulting in the acquisition of 11,686,406 shares (approximately 5.475 percent of SUPERVALU’s outstanding common stock) at a purchase price of $4.00 per share in cash.

Find out more on SVU here:

http://www.wallstreetscoop.net/market-scan/?symbol=SVU


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
info@wallstreetscoop.net
347-905-5009


© Accesswire 2013
Recommend :
0
React to this article
Latest news on ACADIA PHARMACEUTICALS INC
6d ago ACADIA PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
04/03 ACADIA PHARMACEUTICALS : to Present at the 13th Annual Needham Healthcare Confer..
04/01 ACADIA PHARMACEUTICALS : to Present at the 13th Annual Needham Healthcare Confer..
03/12 ACADIA PHARMACEUTICALS : Announces Proposed Public Offering of Common Stock
03/11 ACADIA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financia..
03/11 ACADIA PHARMACEUTICALS INC. : ACADIA Pharmaceuticals Prices Underwritten Public ..
03/06 ACADIA PHARMACEUTICALS INC. : Acadia Pharmaceuticals Reports Proposed Public Off..
03/05 ACADIA PHARMACEUTICALS INC. : ACADIA Pharmaceuticals to Present at Upcoming Inve..
03/05 ACADIA PHARMACEUTICALS INC. : Acadia Pharmaceuticals Posts Financial Results for..
03/04 ACADIA PHARMACEUTICALS INC. : ACADIA Pharmaceuticals Prices Public Offering of C..
Advertisement
Chart
Duration : Period :
ACADIA Pharmaceuticals Inc Technical Analysis Chart | ACAD | US0042251084 | 4-Traders
Income Statement Evolution
ACADIA Pharmaceuticals Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF